1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Pfizer’s Abrysvo Is First RSV Vaccine Approved For Younger High-Risk Adults

 
• By Jessica Merrill

Pfizer beat GSK with a new indication for its RSV vaccine in high-risk individuals aged 18-59.

(Shutterstock)
Key Takeaways
  • Pfizer’s Abrysvo is the first RSV vaccine to be approved in younger adults starting at age 18 who are at increased risk.
  • Pfizer said Abrysvo now offers protection across the broadest spectrum of adults.
  • However, GSK’s Arexvy is close behind, with the company expected to have data in adults aged 18 and older shortly.

The showdown between Pfizer and GSK continues in the respiratory syncytial virus (RSV) vaccine space as Pfizer picked up some leverage with a new US Food and Drug Administration approval...

“Abrysvo now offers the broadest RSV vaccine indication for adults,” Pfizer said in a statement. The vaccine was approved in 2023 for adults aged 60 and older, and later gained...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

More from New Products

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).